Daraxonrasib Delivers Breakthrough Survival Gains in Pancreatic Cancer
Andrew H. Ko, MD
Eileen O'Reilly, MD
Shubham Pant, MD, MBBS
Rachna Shroff, MD, MS, FASCO
Rahul Gosain, MD, MBA
Rohit Gosain, MD
Key Points
- RASolute 302 emerged as a defining pancreatic cancer presentation at ASCO 2026.
- Daraxonrasib doubled overall survival (OS) in previously treated metastatic disease.
- KRAS mutations are present in about 90% to 95% of pancreatic cancers.
- The findings suggest broad applicability beyond narrow molecular subsets.
At a Clinical Insights discussion coinciding with the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Brothers podcast cohosts Rahul Gosain, MD, MBA, of Wilmot Cancer Institute, and Rohit Gosain, MD, of Roswell Park Comprehensive Cancer Center, met with Andrew H. Ko, MD, of the University of California, San Francisco; Eileen O’Reilly, MD, of Memorial Sloan Kettering Cancer Center; Shubham Pant, MD, MBBS, of The University of Texas MD Anderson Cancer Center; and Rachna Shroff, MD, MS, FASCO, of the University of Arizona, to discuss what many described as a defining moment in pancreatic cancer.
The panel emphasized that metastatic pancreatic cancer has historically seen minimal therapeutic progress, with 5-year survival remaining below 5% and limited second-line options following chemotherapy, including modified FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin) and gemcitabine-based regimens. In this context, the emergence of a targeted oral RAS inhibitor with broad applicability represents a major departure from incremental advances of prior decades.
Early discussion centered on the magnitude of benefit observed in RASolute 302, in which daraxonrasib doubled median OS compared with chemotherapy. Importantly, KRAS mutations are present in the overwhelming majority of pancreatic cancers, meaning this was not a narrow biomarker-defined success but rather a potentially broadly applicable advance.
Investigators framed the study as a pivotal shift in pancreatic cancer treatment, moving away from largely cytotoxic sequencing toward pathway-driven therapy targeting the MAP kinase signaling axis that underpins disease biology.